bluebird bio Inc at Goldman Sachs Global Healthcare Conference Transcript
Good afternoon. Thanks, everyone, for joining us. We're really pleased to have the bluebird bio team with us. We have Andrew Obenshain, CEO; Tom Klima, Chief Commercial Officer; and Jason Cole, Chief Strategy and Financial Officer.
And with that, Andrew, I'm going to turn it over to you, but big congratulations for the double unanimous FDA panel last week.
Yes. Thank you very much, Salveen. I think it's -- this was a -- it was a tremendous moment for bluebird, but really it was just a tremendous moment for the industry as well because I think it had a lot of read-through to gene therapy in general.
But specifically for bluebird, for us, it was -- it really had a number of knock-on effects, super positive other than celebrations in the office. We were talking now that we're -- have a high degree of confidence that when our PDUFA dates come in August and September, that we'll get approval. And with that
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
